Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HOWL Stock Forecast 2026-2027
$0.68
Current Price
$33.05M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to HOWL Price Targets
+1,370.6%
To High Target of $10.00
+929.4%
To Median Target of $7.00
+488.2%
To Low Target of $4.00
HOWL Price Momentum
-1.4%
1 Week Change
-20.0%
1 Month Change
-15.0%
1 Year Change
+7.9%
Year-to-Date Change
-71.4%
From 52W High of $2.38
+28.3%
From 52W Low of $0.53
📊 TOP ANALYST CALLS
Did HOWL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Werewolf Therapeutics is one of their latest high-conviction picks.
Latest HOWL Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, HOWL has a bullish consensus with a median price target of $7.00 (ranging from $4.00 to $10.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $0.68, the median forecast implies a 929.4% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Zemansky at B of A Securities, projecting a 1,370.6% upside. Conversely, the most conservative target is provided by Andres Y. Maldonado at HC Wainwright & Co., suggesting a 488.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HOWL Analyst Ratings
3
Buy
0
Hold
0
Sell
HOWL Price Target Range
Low
$4.00
Average
$7.00
High
$10.00
Current: $0.68
Latest HOWL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HOWL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 19, 2025 | HC Wainwright & Co. | Andres Y. Maldonado | Buy | Maintains | $4.00 |
| Nov 18, 2025 | B of A Securities | Jason Zemansky | Buy | Maintains | $7.00 |
| Aug 25, 2025 | B of A Securities | Jason Zemansky | Buy | Maintains | $8.00 |
| Aug 21, 2025 | JMP Securities | Reni J. Benjamin | Market Outperform | Maintains | $3.00 |
| May 9, 2025 | Wedbush | Robert Driscoll | Outperform | Maintains | $6.00 |
| Mar 12, 2025 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $15.00 |
| Mar 12, 2025 | Wedbush | Robert Driscoll | Outperform | Reiterates | $8.00 |
| Jan 14, 2025 | JMP Securities | Reni Benjamin | Market Outperform | Maintains | $4.00 |
| Nov 19, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $15.00 |
| Jul 2, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $15.00 |
| Jun 26, 2024 | JMP Securities | Reni Benjamin | Market Outperform | Reiterates | $12.00 |
| Jun 26, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $15.00 |
| Jun 4, 2024 | JMP Securities | Reni Benjamin | Market Outperform | Reiterates | $12.00 |
| Jun 3, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $15.00 |
| May 24, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $15.00 |
| May 6, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $15.00 |
| May 6, 2024 | JMP Securities | Reni Benjamin | Market Outperform | Reiterates | $12.00 |
| Apr 3, 2024 | JMP Securities | Reni Benjamin | Market Outperform | Initiates | $12.00 |
| Mar 7, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Maintains | $15.00 |
| Nov 15, 2023 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $15.00 |
Werewolf Therapeutics, Inc. (HOWL) Competitors
The following stocks are similar to Werewolf Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
HOWL
Werewolf Therapeutics
mkt cap
33.05M
Werewolf Therapeutics, Inc. (HOWL) Financial Data
Valuation Metrics
Market Cap
$33.05M
Enterprise Value
$-4,584,164
P/E Ratio
N/A
PEG Ratio
-0.7x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+140.6%
Current Ratio
1.3x
Debt/Equity
72.3x
ROE
-161.9%
ROA
-42.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Werewolf Therapeutics, Inc. (HOWL) Business Model
About Werewolf Therapeutics, Inc.
What They Do
Develops innovative cancer immunotherapy treatments.
Business Model
Werewolf Therapeutics Inc. generates revenue by developing conditionally activated biologics that enhance the immune system's ability to target and treat cancer. Their business model focuses on creating proprietary therapies that minimize systemic toxicity while maximizing therapeutic effectiveness, which positions them favorably within the growing oncology market.
Additional Information
The company is recognized for its unique approach to balancing efficacy and safety in cancer therapy. Werewolf Therapeutics is strategically aligned with the increasing investment interest in cancer immunotherapy, as the oncology therapeutics market expands and seeks novel treatment solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
39
CEO
Dr. Daniel J. Hicklin Ph.D.
Country
United States
IPO Year
2021
Website
werewolftx.comWerewolf Therapeutics, Inc. (HOWL) Latest News & Analysis
Latest News
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
3 days ago
Quick Summary
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) reported its Q1 2026 financial results and provided a business update on its immune system-targeting cancer therapies.
Why It Matters
Werewolf Therapeutics' financial results and business update signal its progress in cancer treatment, impacting stock performance and investor confidence in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The company is assessing strategic options aimed at maximizing shareholder value.
Why It Matters
Ongoing evaluation of strategic options signals potential changes that could enhance shareholder value, potentially impacting stock price and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Werewolf Therapeutics (Nasdaq: HOWL) is exploring strategic alternatives to enhance its drug development pipeline and maximize shareholder value, with Piper Sandler as its financial advisor.
Why It Matters
Werewolf Therapeutics is evaluating strategic options to enhance its drug development pipeline, potentially leading to partnerships, acquisitions, or funding, impacting stockholder value and market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Werewolf Therapeutics reported positive initial Phase 1b data for WTX-124 and WTX-330, with high tolerability and antitumor activity. Updates on trials expected in 2026. Two INDs planned by mid-2027.
Why It Matters
Werewolf Therapeutics' promising clinical data for WTX-124 and WTX-330 indicates strong potential for effective cancer treatments, enhancing investor confidence in the company's growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Werewolf Therapeutics (HOWL) has received a Zacks Rank #2 (Buy) upgrade, indicating increased optimism about its earnings prospects, which may lead to a potential stock price increase.
Why It Matters
The Zacks Rank #2 upgrade signals strong earnings potential for Werewolf Therapeutics, likely attracting more buyers and driving the stock price up.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Werewolf Therapeutics presented preclinical data on its INDUCER™ T Cell Engager Platform, highlighting potent antitumor activity and improved safety for its WTX-124 molecule at the SITC meeting.
Why It Matters
The announcement of Werewolf Therapeutics' novel T Cell Engager Platform and promising preclinical results could signal potential advancements in cancer treatment, impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About HOWL Stock
What is Werewolf Therapeutics, Inc.'s (HOWL) stock forecast for 2026?
Based on our analysis of 9 Wall Street analysts, Werewolf Therapeutics, Inc. (HOWL) has a median price target of $7.00. The highest price target is $10.00 and the lowest is $4.00.
Is HOWL stock a good investment in 2026?
According to current analyst ratings, HOWL has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.68. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HOWL stock?
Wall Street analysts predict HOWL stock could reach $7.00 in the next 12 months. This represents a 929.4% increase from the current price of $0.68. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Werewolf Therapeutics, Inc.'s business model?
Werewolf Therapeutics Inc. generates revenue by developing conditionally activated biologics that enhance the immune system's ability to target and treat cancer. Their business model focuses on creating proprietary therapies that minimize systemic toxicity while maximizing therapeutic effectiveness, which positions them favorably within the growing oncology market.
What is the highest forecasted price for HOWL Werewolf Therapeutics, Inc.?
The highest price target for HOWL is $10.00 from Jason Zemansky at B of A Securities, which represents a 1,370.6% increase from the current price of $0.68.
What is the lowest forecasted price for HOWL Werewolf Therapeutics, Inc.?
The lowest price target for HOWL is $4.00 from Andres Y. Maldonado at HC Wainwright & Co., which represents a 488.2% increase from the current price of $0.68.
What is the overall HOWL consensus from analysts for Werewolf Therapeutics, Inc.?
The overall analyst consensus for HOWL is bullish. Out of 9 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are HOWL stock price projections?
Stock price projections, including those for Werewolf Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2026 12:43 PM UTC